Article and Video CATEGORIES
Superior vena cava (SVC) syndrome is an infrequent but not rare complication of lung cancer, occurring in 2-4% of cases, most typically an early symptom that leads to the diagnosis. The SVC is the main vein that drains blood back into the heart from the upper body, and it runs in the middle of the chest on the right side, where it is vulnerable to being compressed by a nearby lung cancer or enlarged lymph nodes, such as from lung cancer or lymphoma. Less commonly, SVC syndrome can be caused by a clot within the blood vessel, and it's also possible to have a combination of external compression and blood clot (clots are more likely to develop where blood flow is compromised). This leads to blockage of the blood flow from the upper body and engorged blood vessels and often swelling of the face, neck, and sometimes upper extremities, as shown in this figure (from this summary article): The leading symptoms of SVC syndrome are facial edema, distended veins in the neck and sometimes chest, arm edema, shortness of breath, cough, facial plethora/fullness, and less commonly wheezing, lightheadedness, headaches, and even confusion.
Although several decades ago infectious issues such as syphylis and TB were common causes of SVC syndrome, it's much more common now to have cancer as a cause today. Specifically, this is usually lung cancer, but lymphoma can also lead to this, and more rarely causes like germ cell tumors in the chest. A few decades ago, cancer was the source of up to 90% of SVC syndromes, but now that indwelling catheters and pacemakers are more common and can lead to clotting within the blood vessels, cancer is the cause in only about 2/3 of cases. The best way to assess this is with a chest CT with intravenous contrast, although ultrasound studies of the upper extremities (OK, arms) can help identify the extent of the backup; MRI scans are also sometimes used, but generally in people who can't receive IV contrast. The diagnosis is made by obtaining tissue, which is sometimes done by draining pleural fluid, since up to 2/3 of patients with SVC syndrome also have a pleural effusion. Whie a thoracentesis (removing fluid around the lung with a needle from the back) is relatively can provide some relief of shortness of breath, it only yields a diagnosis about half of the time. Bronchoscopy works about 50-70% of the time, CT-guided biopsy with a needle from outside of the chest about 75% of the time, and mediastinoscopy somewhere in the range of 90% of the time. Another potential biopsy source would be to excise an enlarged lymph node, such as above the clavicle, which has the advantage of providing a significant amount of tissue to examine. Particularly for lymphoma but also for lung cancer and other malignant causes, haivng more tissue to review is always helpful. Next, we'll turn to management of SVC syndrome.
Please feel free to offer comments and raise questions in our
discussion forums.
Forum Discussions
Hello Janine, thank you for your reply.
Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...
Hi elysianfields,
That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...
Hello Linda, my name is Alexandra Beneke, I'm the Outreach Manager for GRACE. Your willingness to share your experiences and knowledge with the cancer community is truly inspiring. Your dedication to...
Hi Bluebird, Welcome to GRACE. I'm sorry you're going through this scare and hope it's just inflammation or from an infection you didn't know you had.
A CT would be...
Radiation + Brain Operation has just been discarded due to high risk. They will double Tagrisso dosis and then wait to see if it works, then try traditional Chemo. I would...
Recent Comments
That's…
Hi elysianfields and welcome to Grace. I'm sorry to hear about your father's progression.
Unfortunately, lepto remains a difficult area to treat. Recently FDA approved the combo Lazertinib and Amivantamab...